# Swinburne University researchers test sulforaphane against Friedreich ataxia in lab models

- Published: 2026-11-07 14:17 UTC
- Section: Life & Health › Medicine
- Tags: Swinburne University, sulforaphane frataxin, Friedreich ataxia treatment, induced pluripotent stem cells, pediatric neurodegeneration
- URL: https://realtech.media/news/rt-ba99b7828723eb7ff7dcb2dc_swinburne_university_researchers/

**Preclinical experiments show that sulforaphane boosts frataxin levels and protects neurons, opening paths toward clinical trials.**

![Swinburne University researchers test sulforaphane against Friedreich ataxia in lab models](https://realtech.media/media/2026/11/283c9aa006807071.webp)
*sciencedaily.com*

Researchers from Swinburne University of Technology have reported that sulforaphane, a natural compound found in broccoli, increases frataxin levels in preclinical cellular models of Friedreich ataxia, according to sciencedaily.com [1]. The neurodegenerative condition progressively destroys nerve cells in the brain and spinal cord, gradually robbing patients of the ability to coordinate movements, walk, and speak [1]. The underlying genetic defect leads to a critical deficiency of frataxin, a protein required for proper cell function and mitochondrial health, while approximately 200 people currently live with the disease in Australia.

## Cellular protection and biochemical pathways

Using sensory neurons derived from induced pluripotent stem cells, the team demonstrated that sulforaphane does more than stimulate frataxin production [1]. The compound also mitigates cellular stress and dampens inflammatory signaling pathways involved in neuronal degeneration [1]. Frataxin plays an essential role in cells with high metabolic and energy demands, and sulforaphane targets multiple pathogenic factors simultaneously, protecting vulnerable neural structures from structural degradation.

## Transition to clinical trials

Study lead Faith Kwa pointed out that children represent a significant portion of patients, yet no approved pediatric therapies currently exist for Friedreich ataxia [1]. Purified, biologically active forms of sulforaphane are commercially available, and the substance already possesses an established safety record in both adult and pediatric populations [1]. The university researchers are now seeking funding to organize clinical trials to verify whether these preclinical mechanisms yield therapeutic benefits in human patients.

## Sources

1. [sciencedaily.com](https://www.sciencedaily.com/releases/2026/11/261104012259.htm)
2. [ua.news](https://ua.news/en/dovkolo-svitu/sulforafan-mozhe-pidvishchuvati-riven-frataksinu-pri-ataksiyi-fridreikha-sciencedaily)

---

Source: RealTech, realtech.media — https://realtech.media/news/rt-ba99b7828723eb7ff7dcb2dc_swinburne_university_researchers/